参苓白术散加减组方辅助化疗用于晚期结直肠癌的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 参苓白术散加减组方辅助化疗用于晚期结直肠癌的临床观察
TITLE:
摘要: 目的:观察参苓白术散加减组方辅助伊立替康与雷替曲塞用于晚期结直肠癌的疗效和安全性。方法:48例结直肠癌患者随机分为对照组(25例)和观察组(23例)。对照组患者给予注射用盐酸伊立替康160 mg/m2,静脉滴注90 min,d1+注射用雷替曲塞3 mg/m2,静脉滴注,d2。观察组患者在对照组治疗的基础上依据中医证型证候的不同,在每个化疗周期前2 d给予参苓白术散加减中药煎剂治疗,每日1剂,于中、晚餐前2 h温热服用150 ml,连用10 d。化疗以21 d为1个周期,中药10 d为1个周期,两组均治疗2个周期。观察两组患者近期疗效、中医证候改善情况和生存质量改善情况,记录不良反应发生情况。 结果:治疗后,观察组患者生存质量总改善率、中医证候有效率均显著高于对照组,腹泻发生率显著低于对照组,差异均有统计学意义(P<0.05)。两组患者总有效率、疾病控制率、恶心呕吐发生率、肝肾功能损害发生率、骨髓抑制发生率比较差异均无统计学意义(P>0.05)。结论:参苓白术散加减组方辅助伊立替康与雷替曲塞用于晚期结直肠癌疗效较好,可改善患者中医证候,提高生存质量,减轻化疗引起的腹泻,且不增加不良反应的发生。
ABSTRACT: OBJECTIVE: To observe the efficacy and safety of Shenling baishu powder combined with irinotecan and raltitrexed in the treatment of advanced colorectal cancer. METHODS: 48 patients with advanced colorectal cancer were randomly divided into control group (25 cases) and observation group (23 cases). Control group received irinotecan 160 mg/m2, intravenous infusion for 90 min, d1+raltitrexed 3 mg/m2, intravenous infusion, d2. According to different TCM syndrome types, observation group additionally received Shenling baishu powder addition and subtraction of Chinese herbal medicine 2 d before chemotherapy, once a day, for 10 d. 21 d was regarded as a treatment course for chemotherapy and 10 d for TCM, they treated for 2 courses. Clinical efficacy, improvement of TCM syndrome and life quality in 2 groups were observed, and the incidence of adverse reactions was recorded. RESULTS: After treatment, total improvement rate of life quality and improvement rate of TCM syndrome in observation group were significantly higher than control group, the incidence of diarrhea was significantly lower than control group, with statistical significance (P<0.05). There was no significant difference in total effective rate, disease control rate, the incidences of diarrhea, liver and kidney function damage and bone marrow suppression in 2 groups (P>0.05). CONCLUSIONS: Shenling baishu powder addition and sulotraction combined with irinotecan and raltitrexed can significantly reduce the side effects of chemotherapy, improve clinical symptoms and life quality, and do not increase the incidence of adverse rcactions.
期刊: 2016年第27卷第33期
作者: 南宝,李烜
AUTHORS: NAN Bao1,LI Xuan
关键字: 参苓白术散;伊立替康;雷替曲塞;晚期结直肠癌;化疗;疗效;安全性
KEYWORDS: Shenling baishu powder; Irinotecan; Raltitrexed; Advanced colorectal cancer; Chemotherapy; Efficacy; Safety
阅读数: 317 次
本月下载数: 1 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!